Ivosidenib Approved for Acute Myeloid Leukemia & Advanced Ch

Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.

Related Keywords

, European Commission , Servier Pharmaceuticals As Tibsovo , Servier Pharmaceuticals , Acute Myeloid Leukemia , Blood Cancer , Chemotherapy , Targeted Therapy , Cholangiocarcinoma ,